| Ramot At Tel Aviv University Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120129916 | CELL-TARGETING NANOPARTICLES COMPRISING POLYNUCLEOTIDE AGENTS AND USES THEREOF - A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic molecules are not comprised in a liposome; and (b) covalently binding the complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. Use of the particles and compositions comprising same are also disclosed. | 05-24-2012 |
| 20120122657 | RHENIUM NANOSTRUCTURES - The present invention provides atomic Re nanostructures selected from binary Re-metal nanotubes, binary Re-metal nanowires, binary Re-metal nanorods, Re branched nanostructures, and hollow Re nanostructures. | 05-17-2012 |
| 20120120551 | ELECTRODE AND METHOD OF MANUFACTURING THE SAME - A method of fabricating a device is disclosed. The method comprises coating a solid structure by nanostructures selected from the group consisting of peptides and amino acids, under conditions that at least partially prevent assembly of the nanostructures into supramolecular structures. | 05-17-2012 |
| 20120115202 | PHOTOCATALYTIC HYDROGEN PRODUCTION IN CYANOBACTERIA - A cyanobacterial cell comprising a PSI complex which accepts electrons from at least one respiratory cytochrome is disclosed. Methods of generating same and use of same for the production of hydrogen gas are also disclosed. | 05-10-2012 |
| 20120114650 | SINGLE CHAIN ANTIBODIES AGAINST BETA-AMYLOID PEPTIDE - Anti-AβP scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Aβp 1-40 and disaggregate Aβp 1-40 fibrils generated in vitro. The anti-Aβp scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-AβP scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease. | 05-10-2012 |
| 20120114631 | STABLE ENZYMATIC PREPARATIONS AND METHODS OF USE THEREOF - The present invention relates to stable concentrated enzymatic compositions suitable for storage under ambient conditions, while maintaining their intended enzymatic activity. The invention further relate to kits comprising concentrated enzymatic compositions, methods for preparing debriding solutions from said concentrated enzymatic compositions and methods of using the diluted debriding solutions. | 05-10-2012 |
| 20120100158 | ANTI CEACAM1 ANTIBODIES AND METHODS OF USING SAME - A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same. | 04-26-2012 |
| 20120081245 | LINEARIZED OPTICAL DIGITAL-TO-ANALOG MODULATOR - A modulator device for converting digital data into modulation of an optical signal includes an electronic input for receiving an input data word of N bits and an electrically controllable modulator for modulating the intensity of an optical signal, the modulator including M actuating electrodes where M≧N. An electrode actuating device, most preferably a digital-to-digital converter, operates actuating electrodes so that at least one electrode is actuated as a function of values of more than one bit of the input data word. According to an alternative, or supplementary, aspect of the invention, the set of electrodes includes at least one electrode having an effective area which is not interrelated to others of the set by factors of two. In one preferred implementation, a Mach-Zehnder modulator also provides phase modulation to give QAM functionality. Another implementation employs a semiconductor laser. | 04-05-2012 |
| 20120065270 | POTASSIUM ION CHANNEL MODULATORS AND USES THEREOF - Compounds of formula (I) and pharmacologically acceptable salts and pro-drugs wherein: | 03-15-2012 |
| 20120063276 | PEPTIDE NANOSTRUCTURES AND METHODS OF GENERATING AND USING THE SAME - A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid. | 03-15-2012 |
| 20120062760 | IMAGING SYSTEM AND METHOD FOR IMAGING OBJECTS WITH REDUCED IMAGE BLUR - An imaging device is presented for use in an imaging system capable of improving the image quality. The imaging device has one or more optical systems defining an effective aperture of the imaging device. The imaging device comprises a lens system having an algebraic representation matrix of a diagonalized form defining a first Condition Number, and a phase encoder utility adapted to effect a second Condition Number of an algebraic representation matrix of the imaging device, smaller than said first Condition Number of the lens system. | 03-15-2012 |
| 20120061471 | SYSTEM AND A METHOD FOR NANO IMPRINTING - A method for creating a highly accurate nanostructure is provided, the method includes: (i) creating a highly accurate nanostructure prototype, wherein the highly accurate nanostructure prototype, when illuminated with a predefined illumination, provides a unique optical pattern; (ii) creating at least one highly accurate nanostructure mold from the highly accurate nanostructure prototype, wherein each highly accurate nanostructure mold enables a creation of a highly accurate nanostructure that is substantially similar to the highly accurate nanostructure prototype and which, when illuminated with the predefined illumination, provides the unique optical pattern; and (iii) molding the highly accurate nanostructure using the highly accurate nanostructure mold, wherein the highly accurate nanostructure, when illuminated with the predefined illumination, provides the unique optical pattern. | 03-15-2012 |
| 20120060418 | CATALYTIC GASIFICATION OF ORGANIC MATTER IN SUPERCRITICAL WATER - A catalyst system including at least one metal and an oxide support, said oxide support including at least one of Al | 03-15-2012 |
| 20120041521 | LOW-LEVEL ENERGY LASER THERAPY - Methods and systems ( | 02-16-2012 |
| 20120028894 | PEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND USES THEREOF - Use of an isolated peptide comprising an amino acid sequence being no more than 25 amino acids in length, the amino acid sequence comprising at least one aspartate or a homolog thereof, the peptide having an Insulin-Degrading Enzyme (IDE) inhibitory activity, for the manufacture of a medicament identified for treating a disease selected from the group consisting of diabetes, obesity, hyperglycemia, retinal damage, renal failure, nerve damage, microvascular damage and varicella-zoster virus (VZV) infection is disclosed. | 02-02-2012 |
| 20120027833 | DRUG-ELUTING FILMS - Polymeric porous films, capable of eluding a bioactive agent when coming in contact with a physiological medium according to a pre-determined and controlled release profile suitable for particular type of drug and indication, and medical devices including the same are disclosed. Also disclosed are processes for producing the polymeric porous films by freeze-drying an inverted emulsion formulation in which the polymer's composition, the polymer's concentration, the polymer's initial molecular weight, the concentration and/or the type of a surfactant, the homogenization rate and/or the oil phase to aqueous phase ratio (O:A) are selected so as to impart a desired release profile of the bioactive agent from the polymeric film. | 02-02-2012 |
| 20120015878 | USE OF ADNF POLYPEPTIDES FOR TREATING ANXIETY AND DEPRESSION - This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of the invention provide methods for preventing and/or treating anxiety and depression disorders in a subject by administering a NAP, an 8-amino-acid peptide derived from Activity Dependent Neurotrophic Factor (ADNF III), in an amount sufficient to improve postnatal performance. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites and provide neuroprotective and anti-anxiety functions. | 01-19-2012 |
| 20120013911 | DEVICE AND METHOD FOR OPTICAL SENSING OF SUBSTANCES OR ENVIRONMENTAL CONDITIONS - A device for optical sensing of substances or environmental conditions in a fluid includes a number of non-overlapping adjacent sensing elements, each having a layered optical element for generating a wavelength-specific interference effect and being treated so as to respond to the presence of a predefined substance or a predefined environmental condition to cause an optically detectable change. The sensing elements are distinct from each other both in their wavelength-specific interference effect and in the corresponding optically detectable change. As a result, when the device is illuminated by a common illumination beam of multi-wavelength illumination, spectral analysis performed on the reflected or transmitted illumination enables simultaneous sensing of a plurality of substances or environmental conditions. In certain preferred implementations, the layered optical element includes at least one layer of porous silicon. | 01-19-2012 |
| 20120010148 | COMBINATION THERAPIES USING NAP - This invention relates to treatment of neurodegeneration, multiple sclerosis, or schizophrenia using an ADNF III polypeptide in combination with another therapeutic agent. Neurodegeneration, including neurodegeneration caused by dementia-related conditions, such as tauopathies, including Alzheimer's disease, and aging-related dementia, is treated by a combination of an ADNF III polypeptide and an acetylcholinesterase inhibitor. Multiple sclerosis is treated by a combination of an ADNF III polypeptide and glatiramer acetate. Schizophrenia is treated with a combination of an ADNF III peptide and an antipsychotic drug, selected from Aripiprazole, Clozapine, Ziprasidone, Resperidone, Quetiapine, and Olanzapine. | 01-12-2012 |
| 20120009673 | MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES - An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed. | 01-12-2012 |
| 20120004627 | APPARATUS AND METHODS FOR ENZYMATIC DEBRIDEMENT OF SKIN LESIONS - An apparatus for debridement of devitalized tissue in skin lesions, that includes a plurality of height- and angle-adjustable inlet tubes and at least one outlet tube and a member that forms an occlusive seal around a skin lesion. The plurality of inlet tubes is adapted for directing a continuous stream of enzymatic solution to the surface and into the entire volume of the wound bed of the lesion and the at least one outlet is adapted for removing the enzymatic solution, fluids draining from the lesion and tissue debris from the occluded skin lesion. | 01-05-2012 |
| 20120003739 | POPULATIONS OF EXPANDED AND RE-DIFFERENTIATED ADULT ISLET BETA CELLS CAPABLE OF PRODUCING INSULIN AND METHODS OF GENERATING SAME - A population of expanded adult islet beta cells is provided as well as a population of expanded and redifferentiated adult islet beta cells. Methods of generation of the populations of cells are provided. | 01-05-2012 |
| 20110319334 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES - Isolated peptides are provided, being less than 20 amino acids in length. The peptides comprising an amino acid sequence GVLYVGSKTREGV (SEQ ID NO: 12) AAATGLVKREE (SEQ ID NO: 13) or GVVAAAEKTKQG (SEQ ID NO: 14), mimetics and/or fragment thereof, the peptides being capable of inhibiting alpha synuclein aggregation. Pharmaceutical compositions comprising same are also provided as well as uses thereof. | 12-29-2011 |
| 20110317892 | METHOD AND SYSTEM OF CLASSIFYING MEDICAL IMAGES - A method of generating a category model for classifying medical images. The method comprises providing a plurality of medical images each categorized as one of a plurality of categorized groups, generating an index of a plurality of visual words according to a distribution of a plurality of local descriptors in each the image, modeling a category model mapping a relation between each visual word and at least one of the categorized groups according to the index, and outputting the category model for facilitating the categorization of an image based on local descriptors thereof. | 12-29-2011 |
| 20110313314 | METHOD AND SYSTEM FOR DETECTING NEUROPATHY - The invention provides a system and method for detecting or monitoring neuropathy in an individual. The system of the invention includes a platform having a surface in which a plurality of stimulators is embedded. Each stimulator is configured to stimulate a region in a skin area when the skin area is applied to the platform. The stimulators may deliver thermal and/or vibrational energy to the skin region. In the method of the invention, a skin area is applied to platform and one of the stimulators is activated. A minimal stimulation is determined that is sensed by the individual in a skin region in contact with a stimulator. Neuropathy in the skin region in contact with the stimulator is detected if either the determined minimal stimulation is above a predetermined threshold, or if a stimulation is not sensed before a magnitude of the stimulation reaches a predetermined maximal magnitude. The process is then repeated with other stimulators. | 12-22-2011 |
| 20110306571 | Methods for treating cancer - Use of a macrolide antibiotic for the manufacture of a medicament for the treatment or prevention of a cancer selected from colorectal cancer, Desmoid tumor, bladder cancer, gastric cancer, and breast cancer, the macrolide antibiotic being one or more of: tylosin, pharmaceutically acceptable salts thereof, and derivatives thereof; erythromycin, pharmaceutically acceptable salts thereof, and derivatives thereof; oleandomycin, pharmaceutically acceptable salts thereof, and derivatives thereof; and spiramycin, pharmaceutically acceptable salts thereof, and derivatives thereof. Also provided are pharmaceutical compositions and methods for the treatment or prevention of the above mentioned cancers and methods for treating or preventing, in a mammal, a cancer that expresses a mutated APC gene. | 12-15-2011 |
| 20110289286 | MEMORY CONTROLLER AND A METHOD FOR WRITING INFORMATION TO A K-LEVEL MEMORY UNIT - A method, a computer readable medium and a memory controller. The method for writing information to a K-level memory unit, includes: receiving a sequence of information bits; generating an information value that represents the sequence of information bits; applying a first function to the information value, to provide a first function result; selecting a first cell of the K-level memory unit as a current cell; wherein K is a positive integer that is greater than 1; writing the first function result to the first cell; and repeating the stages of: (a) reading a current cell to provide a current read result; (b) applying a second function to the current read result and to a function result that was written to the current cell, to provide a second function result; (c) selecting another cell as a current cell; and (d) writing the second function result to the current cell. | 11-24-2011 |
| 20110287068 | FIBRIN AND FIBRINOGEN MATRICES AND USES OF SAME - There is provided compositions-of-matter comprising fibrin or fibrinogen crosslinked with at least one reducing sugar. | 11-24-2011 |
| 20110286971 | TARGETED DRUG-CARRYING BACTERIOPHAGES - The present invention relates to the field of drug delivery. More specifically, the invention relates to the preparation and use of a bacteriophage conjugated through a labile/non labile linker or directly to at least 1,000 therapeutic drug molecules such that the drug molecules are conjugated to the outer surface of the bacteriophage. The bacteriophage optionally displays on its coat a ligand that endows it with specificity towards target cells. Thus, there is provided a targeted, high-capacity drug delivery system useful for the treatment of various pathological conditions. | 11-24-2011 |
| 20110286970 | METHOD FOR TREATING PARKINSON'S DISEASE - The present invention relates to the use of a filamentous bacteriophage, which displays an antibody that specifically binds to a pro-inflammatory cytokine, either alone or in combination with a filamentous bacteriophage that does not display a mammalian cell internalization signal, to treat Parkinson's disease. | 11-24-2011 |
| 20110276856 | METHOD AND DEVICE FOR MULTI PHASE ERROR-CORRECTION - Data bits to be encoded are split into a plurality of subgroups. Each subgroup is encoded separately to generate a corresponding codeword. Selected subsets are removed from the corresponding codewords, leaving behind shortened codewords, and are many-to-one transformed to condensed bits. The final codeword is a combination of the shortened codewords and the condensed bits. A representation of the final codeword is decoded by being partitioned to a selected subset and a plurality of remaining subsets. Each remaining subset is decoded separately. If one of the decodings fails, the remaining subset whose decoding failed is decoded at least in part according to the selected subset. If the encoding and decoding are systematic then the selected subsets are of parity bits. | 11-10-2011 |
| 20110276749 | MULTI-BIT-PER-CELL FLASH MEMORY DEVICE WITH NON-BIJECTIVE MAPPING - To store a plurality of input bits, the bits are mapped to a corresponding programmed state of one or more memory cells and the cell(s) is/are programmed to that corresponding programmed state. The mapping may be many-to-one or may be an “into” generalized Gray mapping. The cell(s) is/are read to provide a read state value that is transformed into a plurality of output bits, for example by maximum likelihood decoding or by mapping the read state value into a plurality of soft bits and then decoding the soft bits. | 11-10-2011 |
| 20110266517 | PEPTIDE NANOSTRUCTURES ENCAPSULATING A FOREIGN MATERIAL AND METHOD OF MANUFACTURING SAME - A composition comprising a material at least partially enclosed by a tubular, spherical or planar nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid. | 11-03-2011 |
| 20110264981 | ERROR CORRECTION DECODING BY TRIAL AND ERROR - A representation of a codeword is decoded by applying a first decoder of the codeword to the representation of the codeword. If applying the first decoder fails to decode the representation of the codeword then a second decoder of the codeword is applied to the representation of the codeword. Preferably, applying the first decoder consumes less power and is faster than applying the second decoder. Data are ported by encoding the data as a codeword, exporting the codeword to a corrupting medium, importing a representation of the codeword, and applying a first decoder to the representation of the codeword. If applying the first decoder fails to decode the representation of the codeword then a second decoder of the codeword is applied to the representation of the codeword. | 10-27-2011 |
| 20110262447 | HUMAN SYNTHETIC SINGLE-CHAIN ANTIBODIES DIRECTED AGAINST THE COMMON EPITOPE OF MUTANT P53 AND THEIR USES - Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention. | 10-27-2011 |
| 20110258370 | MULTIPLE PROGRAMMING OF FLASH MEMORY WITHOUT ERASE - To store, successively, in a plurality of memory cells, first and second pluralities of input bits that are equal in number, a first transformation transforms the first input bits into a first plurality of transformed bits. A first portion of the cells is programmed to store the first transformed bits according to a mapping of bit sequences to cell levels, but, if the first transformation has a variable output length, only if there are few enough first transformed bits to fit in the first cell portion. Then, without erasing a second cell portion that includes the first portion, if respective levels of the cells of the second portion, that represent a second plurality of transformed bits obtained by a second transformation of the second input bits, according to the mapping, are accessible from the current cell levels, the second portion is so programmed to store the second transformed bits. | 10-20-2011 |
| 20110245250 | POTASSIUM ION CHANNEL MODULATORS & USES THEREOF - Compounds of formula (I) and pharmacologically acceptable salts and pro-drugs thereof wherein: | 10-06-2011 |
| 20110242645 | SYSTEM AND METHOD FOR CONTROLLING OPTICAL OUTPUT OF A FREQUENCY CONVERSION DEVICE - A system and method for improving conversion efficiency of a difference frequency generator (DFG) and/or for outputting a desired shape of the output signal, where the method includes providing a pump source, modifying the pump pulse temporal shape for optimal DFG conversion efficiency, and providing the modified pump pulse to the DFG. The pump source may be, for example, a MOPA laser or a diode or any other suitable source. In one embodiment, the pump pulse shape is modified such that an initial gain within the DFG is high, followed by a lower level signal for efficient conversion within the DFG. An example of such a shape is a double square pulse. Other configurations are possible as well such as a single rectangular pulse shape. | 10-06-2011 |
| 20110224184 | NAPHTHOQUINONE DERIVATIVES USEFUL FOR PREVENTION OF AMYLOID DEPOSITS AND TREATMENT OF DISEASES INVOLVING AMYLOIDOGENESIS - The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid. | 09-15-2011 |
| 20110222763 | DEVICES AND METHODS OF READING MONOCHROMATIC PATTERNS - A method of extracting data from an identifiable monochromatic pattern. The method comprises separating a polychromatic optical signal, received from an object having identifiable monochromatic pattern, into a plurality of wavelength components, separately capturing each of the wavelength components, reconstructing a plurality of images each from a different wavelength component, detecting the identifiable monochromatic pattern in one or more of the images, and extracting data associated with or encoded by the detected identifiable monochromatic pattern. The images have different depths of field. | 09-15-2011 |
| 20110215716 | NANOMATRIX SEPARATION OF CHROMOPHORES AND USES THEREOF IN LUMINESCENT DEVICES - A system and process for controlling electronic interactions between two or more interactable materials. | 09-08-2011 |
| 20110212896 | PEPTIDES FOR THE TREATMENT OF OXIDATIVE STRESS RELATED DISORDERS - Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder. | 09-01-2011 |
| 20110210309 | TUBULAR NANOSTRUCTURES, PROCESSES OF PREPARING SAME AND DEVICES MADE THEREFROM - Novel methods of producing single-walled and multi-walled, single-crystalline, tubular nanostructures, made of an inorganic substance (e.g., silicon), and single-walled and multi-walled, single-crystalline, tubular nanostructures produced thereby, are disclosed. Also disclosed are devices into which the nanostructures are integrated. The methods described herein are used to reproducibly and controllably producing single-crystalline nanostructures with well-defined shape, diameter and/or interwall distance, chemical composition and morphology. | 09-01-2011 |
| 20110200692 | USE OF A CINNAMON BARK EXTRACT FOR TREATING AMYLOID-ASSOCIATED DISEASES - The present application disclosed the use of a cinnamon extract in the treatment of amyloid-associated diseases and disorders, such as Alzheimer's disease. | 08-18-2011 |
| 20110197428 | OPTICAL MASK FOR ALL-OPTICAL EXTENDED DEPTH-OF-FIELD FOR IMAGING SYSTEMS UNDER INCOHERENT ILLUMINATION - A method of optical element manufacturing, the method may include selecting a range of a misfocus parameter ψ; and designing the optical element to comprise multiple regions, wherein the optical transfer function (OTF) of the optical element allows, for the range of the misfocus parameter ψ, transmission of images with a contrast of at least 10% for all normalized spatial frequencies up to 50% of a theoretical maximum that is attainable with a full aperture in an in-focus condition. | 08-18-2011 |
| 20110188047 | ENHANCED SENSITIVITY INTERFEROMETRIC SENSORS | 08-04-2011 |
| 20110182118 | ADAPTIVE DYNAMIC READING OF FLASH MEMORIES - Each of a plurality of flash memory cells is programmed to a respective one of L≧2 threshold voltage states within a threshold voltage window. Values of parameters of threshold voltage functions are adjusted in accordance with comparisons of the threshold voltages of some or all of the cells to two or more of m≧2 threshold voltage intervals within the threshold voltage window. Reference voltages for reading the cells are selected based on the values. Alternatively, the m threshold voltage intervals span the threshold voltage window, and respective threshold voltage states are assigned to the cells based on numbers of cells whose threshold voltages are in the intervals, without re-reading the cells. | 07-28-2011 |
| 20110174064 | METHOD AND SYSTEM FOR EMITTING LIGHT - A method of predicting formation of an amyloid plaque in a peptide sample is disclosed. The method comprises determining presence of quantum confinement in the sample, and predicting that formation of an amyloid plaque is likely to occur if the sample exhibits quantum confinement. | 07-21-2011 |
| 20110173143 | SYSTEM AND METHOD FOR ANALYZING EXPLORATORY BEHAVIOR - The invention provides a system and method for analyzing a subject's exploratory behavior. The system of the invention includes a tracking device configured to track motion of the subject and to generate a signal indicative of the subject's motion. A CPU analyzes the signal and identifies in the signal sequences of repeated motions, or sequences of sequences of repeated motion, for sequence of repeated motion, the CPU determines for each occurrence of the repeated motion a time at which the occurrence occurred or a time interval during which the occurrence occurred. The CPU then calculates for each occurrence of the repeated motion a value of one or more predetermined parameters of the occurrence of the motion and then calculates a time dependence of the one or more predetermined parameters during the sequence of repeated motion or the sequence of sequences of repeated motion. | 07-14-2011 |
| 20110171137 | NOVEL NANOSTRUCTURES AND PROCESS OF PREPARING SAME - A process of preparing a plurality of nanostructures, each being composed of at least one target material is disclosed. The process comprises sequentially electrodepositing a first material and the at least one target material into pores of a porous membrane having a nanometric pore diameter, to thereby obtain within the pores nanometric rods, each of the nanometric rods having a plurality of segments where any two adjacent segments are made of different materials. The process further comprises and etching the membrane and the first material, thereby obtaining the nanostructures. | 07-14-2011 |
| 20110163045 | METHOD AND SYSTEM FOR TREATING CONTAMINATED WATER - Methods and systems for treatment, remediation, and purification of contaminated water at an optimal pH for are provided herein, as well as a database for use in said methods and systems. The methods and systems are based on identifying one or more contaminants in the contaminated water, and identifying an optimal pH for performing direct photodegradation of the contaminant(s). | 07-07-2011 |
| 20110162870 | METAL NANOWIRE THIN-FILMS - A conductive nanowire film based on a high aspect-ratio metal is disclosed. The nanowire film is produced by inducing metal reduction in a concentrated surfactant solution containing metal precursor ions, a surfactant and a reducing agent. The metal nanostructures demonstrate utility in a great variety of applications. | 07-07-2011 |
| 20110160629 | CERVICAL COLLAR - The present invention discloses a novel cervical collar for maintaining the airways in head and neck immobilized trauma patient open. This collar comprises a rigid motion-restricting frame ( | 06-30-2011 |
| 20110156109 | METHOD AND SYSTEM FOR MANIPULATING ORGANIC NANOSTRUCTURES - A method of manipulating an organic nanostructure is disclosed. The method comprises: contacting a liquid sample having the organic nanostructure therein with an arrangement of electrodes, and applying voltage to the arrangement of electrodes to manipulate and immobilize the organic nanostructure over the electrodes by electrokinetics. | 06-30-2011 |
| 20110155587 | SYSTEM AND METHOD FOR DETECTING A SUBSTANCE IN LIQUID - A system for analyzing a liquid is provided. The system comprises:
| 06-30-2011 |
| 20110151538 | AFFINITY PURIFICATION BY COHESIN-DOCKERIN INTERACTION - The present invention is directed to truncated dockerin polypeptides, recombinant polypeptides and affinity systems comprising the truncated dockerin polypeptide, methods of generating same, and methods of use thereof to purify, isolate, and detect molecules of interest. | 06-23-2011 |
| 20110150761 | POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, ANTIBODIES THEREAGAINST AND METHODS OF USING SAME FOR DIAGNOSING AND TREATING CANCER AND SKELETAL DISORDERS - An isolated polypeptide is provided, comprising an amino acid sequence being at least 88% homologous to SEQ ID NO: 15 (human) as determined by BlastP using default parameters, the isolated polypeptide being capable of promoting cell adhesion and/or cell homing. | 06-23-2011 |
| 20110149340 | METHOD, SYSTEM AND COMPUTER PROGRAM PRODUCT FOR MANIPULATING A GRAPHIC ENTITY - A system, a method and a computer program product for manipulating a graphic entity. The method includes: receiving first cage vertices information, second cage vertices information and second cage face orientation information; wherein the graphic entity is at least partially surrounded by the first cage and wherein a transformed graphic entity is expected to be is at least partially surrounded by the second cage; transforming the graphic entity to provide a transformed graphic entity in response to information representative of the graphic entity, second cage vertices information and second cage face orientation information. | 06-23-2011 |
| 20110143995 | NOVEL ANTI-ALLERGIC AGENTS - The present invention discloses novel complex molecules useful as anti-allergic agents. These complex molecules include in particular, peptidic or peptidomimetic molecules, having a first segment which is competent for cell penetration and a second segment which is able to reduce or abolish mast cell degranulation, and in particular to reduce or abolish allergy mediators such as histamine secretion from mast cells. Specific examples of peptides with the desired activity are disclosed. | 06-16-2011 |
| 20110142858 | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation - Unglycosylated anti-amyloid antibodies maintained all the antigen recognition functions of the native glycosylated anti-amyloid antibodies but without, or with a much reduced, property of triggering Fc receptor-mediated inflammation response in the brain. Such unglycosylated antibodies can be used in a method for preventing, inhibiting, or treating a disease or disorder characterized by amyloid aggregation with a diminished risk of triggering or exacerbating neuroinflammation. | 06-16-2011 |
| 20110142803 | METHOD FOR TREATING INFLAMMATION ASSOCIATED WITH AMYLOID DEPOSITS AND BRAIN INFLAMMATION INVOLVING ACTIVATED MICROGLIA - Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits. | 06-16-2011 |
| 20110142764 | CONJUGATES OF A POLYMER, A BISPHOSPHONATE AND AN ANTI-ANGIOGENESIS AGENT AND USES THEREOF IN THE TREATMENT AND MONITORING OF BONE RELATED DISEASES - Conjugates of polymers or copolymers having attached thereto an anti-angiogenesis agent and a bisphosphonate bone targeting agent, and processes of preparing same, are disclosed. | 06-16-2011 |
| 20110130369 | USE OF FTS FOR THE TREATMENT OF MYOCARDIAL ISCHEMIA/REPERFUSION INJURY - Disclosed are methods for reducing the extent of myocardial ischemia/reperfusion injury, comprising administering to a human prior to reperfusion of the ischemic myocardium or pre-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof. Methods of treating ischemia/reperfusion injury, comprising administering to a human after reperfusion of the ischemic myocardium or post-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof are also disclosed. | 06-02-2011 |
| 20110121258 | RECTIFYING ANTENNA DEVICE WITH NANOSTRUCTURE DIODE - A rectifying antenna device is disclosed. The device comprises a pair of electrode structures, and at least one nanostructure diode contacting at least a first electrode structure of the pair and being at least in proximity to a second electrode structure of the pair. At least one electrode structure of the pair receives AC radiation, and the nanostructure diode(s) at least partially rectifies a current generated by the AC radiation. | 05-26-2011 |
| 20110104225 | POLYPEPTIDES, MATRICES, HYDROGELS AND METHODS OF USING SAME FOR TISSUE REGENERATION AND REPAIR - A novel laminin polypeptide comprising the amino acid sequence set forth by SEQ ID NO:3 is disclosed. Also disclosed are compositions-of-matter comprising a polysaccharide (e.g., hyaluronic acid) and the novel laminin polypeptide; or hyaluronic acid, a laminin polypeptide and an antioxidant (e.g., superoxide dismutase), as well as matrices and hydrogels comprising same which can be used for ex vivo or in vivo tissue formation and for treatment of pathologies characterized by diseased, damaged or loss of tissue. | 05-05-2011 |
| 20110091515 | DRUG-ELUTING MEDICAL DEVICES - Composite structures composed of a device as a core structure, being a medical device or article, and a porous polymeric coat and designed capable of encapsulating bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures. | 04-21-2011 |
| 20110090721 | CAPACITIVE MATRIX CONVERTERS - A direct current (DC) to DC converter, including: input ports for receiving an input DC voltage; output ports for outputting an output DC voltage; a first matrix of capacitors and switches; a second matrix of capacitors and switches; and a control circuit, coupled to the switches of the first and second matrices, configure d to repetitively: (i) configure the first matrix to a charge configuration and couple the first matrix to the input ports while configuring the second matrix to a discharge configuration and coupling the second matrix to the output ports; (ii) maintain the charge and discharge configurations for a first period of time; (iii) configure the second matrix to the charge configuration and couple the second matrix to the input ports while configuring the first matrix to the discharge configuration and couple the first matrix to the output ports; and (iv) maintain the charge and discharge configurations for a second period of time; (a) wherein the charge configuration and the discharge configurations of each matrix out of the first and second matrices differ from each other by a replacement of serial connections of capacitors of the matrix to parallel connections of capacitors of the matrix; (b) wherein the charge configuration and a discharge configuration of each of the first and second matrices are responsive to required conversion ratio between the input DC voltage and the output DC voltage; and (c) each matrix of the first and second matrices comprises at least four capacitors. | 04-21-2011 |
| 20110085979 | CONJUGATE OF A POLYMER, AN ANTI-ANGIOGENESIS AGENT AND A TARGETING MOIETY, AND USES THEREOF IN THE TREATMENT OF BONE RELATED ANGIOGENESIS CONDITIONS - Conjugates of hydroxypropyl methacrylamide (HPMA)-derived copolymers having attached thereto TNP-470 and a high load (e.g., higher than 3 mol %) of alendronate (ALN), and processes of preparing same are disclosed. | 04-14-2011 |
| 20110082090 | COMPOUNDS SUITED AS NANOCARRIERS FOR ACTIVE AGENTS AND THEIR USE - The invention relates to a compound suited as entity carrier, having the general formula (I) | 04-07-2011 |
| 20110070249 | IMMUNIZING COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST THE Beta-SECRETASE CLEAVAGE SITE OF AMYLOID PRECURSOR PROTEIN - The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of AβPP using this immunizing composition. The present invention is also directed to antibodies against the β-secretase cleavage site of AβPP and their use in a method for inhibiting the formation of amyloid β. | 03-24-2011 |
| 20110064717 | Homing endonuclease genes and their targets - The invention provides pharmaceutical composition having as an active ingredient either a homing endonuclease (HE) capable of cleaving a non-native target nucleotide sequence in a genome or a nucleotide sequence encoding for a HE capable of cleaving a target site in a non-native genome. The invention also provides uses for such HEs, and methods of treatment utilizing such HEs. The HE may be, for example, any one of the HEs PI-SceI, POLB HE, PRP8 HE, or Nostoc species PCC7120 HE. | 03-17-2011 |
| 20110059070 | Combination therapy for tumoral desease treatment - The invention provides a method of treating cancer by administering to a subject in need thereof, the subject being treated with an anti-cancer antibody therapy, a therapeutically effective amount of a delocalized lipophilic cation (DLC) compound such as MKT-077 which is capable of binding mortalin as an adjuvant for the anti-cancer antibody therapy. Also provided are pharmaceutical compositions and article of manufacturer for treating cancer which comprise the DLC compound as an adjuvant for anti-cancer antibody therapy. | 03-10-2011 |
| 20110053022 | DIRECT LIQUID FUEL CELL HAVING HYDRAZINE OR DERIVATIVES THEREOF AS FUEL - A fueled cell system comprising: an anode compartment comprising a compound having the formula R1R2N—NR3R4, a salt, a hydrate or a solvate thereof, as fuel, and a catalyst layer which comprises copper or a copper alloy; | 03-03-2011 |
| 20110048130 | Micro Scale Mechanical Rate Sensors - An angular rate sensor device is presented. The sensor device comprises a disk-shaped structure having a proof mass region and a flexible portion. The disk-like structure is coupled to a substrate in a manner enabling a wave type precession motion such that during the wave type precession motion each material point of the proof mass performs elliptic motion. | 03-03-2011 |
| 20110046223 | TREATMENT OF NEUROFIBROMATOSIS - Disclosed are methods of treating neurofibromatosis by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with colchicine. Also disclosed are pharmaceutical compositions comprising FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof; colchicine; and a pharmaceutically acceptable carrier. | 02-24-2011 |
| 20110045351 | High-Power Nanoscale Cathodes for Thin-Film Microbatteries - A method, including placing a substrate of a battery in a bath consisting of a metal M chosen from a metal group consisting of Fe, Ni, Co, Cu, W, V, and Mn, an oxidant selected from an oxidant group consisting of oxygen and sulfur, and a polymer. The method also includes applying an electrical current so as to form on the substrate a metal M compound cathode having a nanoscale grain structure. | 02-24-2011 |
| 20110039176 | DIRECT LIQUID FUEL CELL HAVING AMMONIA BORANE OR DERIVATIVES THEREOF AS FUEL - Fuel cell systems comprising ammonia borane or derivatives thereof as fuel and an anode and/or cathode which comprises a non-noble metal (e.g., copper) or a non-metallic substance (e.g., an iron electron-transfer mediating complex) as a catalyst are disclosed. Fuel cell systems comprising ammonia borane or derivatives thereof as fuel and a peroxide as an oxidant are also disclosed. Uses of the fuel devices are further disclosed. | 02-17-2011 |
| 20110038914 | CORAL-DERIVED COLLAGEN AND METHODS OF FARMING SAME - An isolated collagen fiber is disclosed, wherein a length of the fiber prior to stretching by about 15%, is identical to a length of the fiber following said stretching by about 15%. The fiber comprises a Nuclear Magnetic Resonance (NMR) spectroscopic profile as shown in FIG. | 02-17-2011 |
| 20110034553 | NOVEL CONJUGATES FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS - A conjugate comprising L-DOPA covalently linked to at least one y-aminobutyric acid (GABA) moiety, an ester and/or an addition salt thereof are disclosed, as well as uses thereof for treating a neurodegenerative disease or disorder. | 02-10-2011 |
| 20110029754 | MULTI-BIT-PER-CELL FLASH MEMORY DEVICE WITH NON-BIJECTIVE MAPPING - To store a plurality of input bits, the bits are mapped to a corresponding programmed state of one or more memory cells and the cell(s) is/are programmed to that corresponding programmed state. The mapping may be many-to-one or may be an “into” generalized Gray mapping. The cell(s) is/are read to provide a read state value that is transformed into a plurality of output bits, for example by maximum likelihood decoding or by mapping the read state value into a plurality of soft bits and then decoding the soft bits. | 02-03-2011 |
| 20110028497 | NOVEL DERIVATIVES OF PURINIC AND PYRIMIDINIC ANTIVIRAL AGENTS AND USE THEREOF AS POTENT ANTICANCER AGENTS - Novel N-acylated, O-acylated and (bis or tris)-N,O-acylated derivatives of purinic and pyrimidinic nucleoside analogs, pharmaceutical compositions containing same, and uses thereof for treating proliferative diseases or disorders are disclosed. | 02-03-2011 |
| 20110022927 | COMPACT DECODING OF PUNCTURED CODES - k information bits are encoded according to a code with which is associated a parity check matrix H that has n columns. The entire resulting codeword is stored in a storage medium. At least n′| 01-27-2011 | |
| 20110022922 | COMPACT DECODING OF PUNCTURED BLOCK CODES - k input bits are encoded according to a code with which is associated a m×n=m+k parity check matrix H. The resulting codeword is punctured, with n′| 01-27-2011 | |
| 20110022921 | COMPACT DECODING OF PUNCTURED BLOCK CODES - k input bits are encoded according to a code with which is associated a m×n=m+k parity check matrix H. The resulting codeword is punctured, with n′| 01-27-2011 | |
| 20110022920 | COMPACT DECODING OF PUNCTURED BLOCK CODES - k input bits are encoded according to a code with which is associated a m×n=m+k parity check matrix H. The resulting codeword is punctured, with n′| 01-27-2011 | |
| 20110012096 | PHOTOACTIVE NANOSTRUCTURE AND METHOD OF MANUFACTURING SAME - A nanostructure comprising at least one semiconductor nanoparticle bound to a photocatalytic unit of a photosynthetic organism is disclosed. The nanoparticle and a binding between the nanoparticle and the photocatalytic unit are selected such that transfer of electrons from the photocatalytic unit to the nanoparticle is prevented or suppressed relative to transfer of excitons from the nanoparticle to the photocatalytic unit. Uses of same and methods of fabricating devices with same are also disclosed. Nanostructures comprising electrically conductive nanoparticles are also disclosed. | 01-20-2011 |
| 20110008422 | SYSTEM FOR DELIVERY OF PROTEIN IN INSOLUBLE FIBRILLAR OR AGGREGATE FORM - A pharmaceutical composition containing a therapeutic protein which is particularly amenable to oral administration by providing stability in the gastrointestinal tract. Insoluble fibrils or aggregates of the therapeutic protein in the pharmaceutical composition are encapsulated in a lipidated glycosaminoglycan particle, coated with a multi-layer of lipids and lipid-glycosaminoglycan conjugates, or present as unencapsulated and uncoated insoluble fibrils or aggregates. | 01-13-2011 |
| 20110003337 | IMMUNOGLOBULIN COMPOSITIONS AND METHODS OF PRODUCING SAME - 1. A method of producing an immunoglobulin in a bacterial culture, the method comprising: | 01-06-2011 |
| 20110001842 | METHOD OF AND APPARATUS FOR PROCESSING IMAGES - A method suitable for processing a digital image is disclosed. The method comprises, for each picture element of the digital image, processing an achromatic intensity level of the picture element using a first adaptation procedure featuring a first effective saturation function of the achromatic intensity, to provide a first intermediate intensity level. The method further comprises processing the achromatic intensity level using a second adaptation procedure featuring a second effective saturation function of the achromatic intensity, to provide a second intermediate intensity level. The method further comprises combining the first and the second intermediate intensity levels to provide a new achromatic intensity level associated with the picture-element. | 01-06-2011 |
| 20100322856 | Compositions and Methods for Inducing Angiogenesis - An isolated peptide comprising an amino acid sequence HWRR as set forth by SEQ ID NO:5, the peptide consists of 4 or 5 amino acids, is provided. Also provided are methods of treating angiogenesis-related pathologies using the peptide of the invention or pharmaceutical compositions comprising same. | 12-23-2010 |
| 20100317724 | METHOD FOR SEARCHING FOR HOMING ENDONUCLEASES, THEIR GENES AND THEIR TARGETS - A computer implemented method for generating nucleotide sequences containing candidate homing endonuclease genes (HEGs). A search is performed in a database stored on a storage medium of nucleotide sequences for amino acid sequences having a subsequence having a homology level with the translation of a subsequence of one or more predetermined HEGs. For each amino acid sequence generated by the search, one or more nucleotide sequences are retrieved encoding the amino acid sequence. The results of this search used in a second search of a database stored on a storage medium to generate the HEG containing sequences. | 12-16-2010 |
| 20100291828 | PEPTIDE NANOSTRUCTURES CONTAINING END-CAPPING MODIFIED PEPTIDES AND METHODS OF GENERATING AND USING THE SAME - A nanostructure composed of a plurality of peptides, each peptide containing at least one aromatic amino acid, whereby one or more of these peptides is end-capping modified, is disclosed. The nanostructure can take a tubular, fibrillar, planar or spherical shape, and can encapsulate, entrap or be coated by other materials. Methods of preparing the nanostructure, and devices and methods utilizing same are also disclosed. | 11-18-2010 |
| 20100287440 | MATRIX STRUCTURE FOR BLOCK ENCODING - A plurality of information bits are encoded using a parity-check matrix that is equivalent to a modular code matrix. The modular code matrix is a diagonal sub-matrix structure immediately above a connection layer that includes a plurality of diverse connection layer sub-matrices, all but at most one of which are below corresponding diagonal matrix structure sub-matrices. The information bits are assembled with a plurality of parity bits produced by the encoding to provide a codeword that is exported to a medium. Preferably, all the diagonal matrix structure sub-matrices are identical. Preferably, some of the parity bits are computed using only diagonal matrix structure sub-matrices. | 11-11-2010 |
| 20100284964 | CANCER THERAPY - The subject invention provides for cancer therapy. | 11-11-2010 |
| 20100279990 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR | 11-04-2010 |
| 20100278841 | DOWN-REGULATION OF MORTALIN BY siRNA - Use of a siRNA molecule selected from the group consisting of SEQ ID NO: 173 to 344 for treating a disease associated with a pathological cell population in a subject in need thereof is disclosed. Pharmaceutical compositions and articles of manufacture comprising the siRNAs are also disclosed. | 11-04-2010 |
| 20100278789 | METHODS OF GENERATING EXPANDED AND RE-DIFFERENTIATED ADULT ISLET BETA CELLS CAPABLE OF PRODUCING INSULIN - A method of increasing insulin content in adult islet beta cells is disclosed. The method comprises contacting the adult islet beta cells with an agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway, the component being up-regulated in beta cell dedifferentiation above a predetermined threshold, thereby increasing the insulin content in adult islet beta cells. Methods of labeling dedifferentiated adult islet beta cells are also disclosed. Cell populations generated using the methods of the present invention and uses thereof are also disclosed. | 11-04-2010 |
| 20100272184 | System and Method for Real-Time Super-Resolution - A method and system are presented for real time Super-Resolution image reconstruction. According to this technique, data indicative of a video frame sequence compressed by motion compensated compression technique is processed, and representations of one or more video objects (VOs) appearing in one or more frames of said video frame sequence are obtained. At least one of these representations is utilized as a reference representation and motion vectors, associating said representations with said at least one reference representation, are obtained from said data indicative of the video frame sequence. The representations and the motion vectors are processed, and pixel displacement maps are generated, each associating at least some pixels of one of the representations with locations on said at least one reference representation. The reference representation is re-sampled according to the sub-pixel accuracy of the displacement maps, and a re-sampled reference representation is obtained. Pixels of said representations are registered against the re-sampled reference representation according to the displacement maps, thereby providing super-resolved image of the reference representation of said one or more VOs. | 10-28-2010 |
| 20100260750 | Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity - Novel serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation. | 10-14-2010 |
| 20100260401 | METHOD AND DEVICE FOR PROCESSING COMPUTERIZED TOMOGRAPHY IMAGES - A method of processing a computerized tomography image is disclosed. The method comprises preprocessing the image using contrast enhancement weight function, thereby providing a preprocessed image having a first dynamic range; and applying a companding procedure to the preprocessed image, so as to reduce the first dynamic range. | 10-14-2010 |
| 20100250737 | DETECTING AND CONTROLLING PEER-TO-PEER TRAFFIC - A method for communication management includes detecting addresses of peer nodes ( | 09-30-2010 |
| 20100247558 | PEPTIDES INDUCING A CD4i CONFORMATION IN HIV gp120 WHILE RETAINING VACANT CD4 BINDING SITE - A novel peptides are complexed with HIV-I envelope protein gp120, and causes the protein to assume a CD4i conformation but without occluding the CD4 binding-site of gp120. This peptide-gp120 complex is immunogenic and, upon immunization of subjects, induces broadly-neutralizing antibodies directed to the CD4 binding site of gp120. The peptide preferably consists of a sequence of 8-20 amino acid residues which comprises (a) a core sequence Arg-Xaa | 09-30-2010 |
| 20100230276 | DEVICE AND METHOD FOR THIN FILM DEPOSITION USING A VACUUM ARC IN AN ENCLOSED CATHODE-ANODE ASSEMBLY - A vacuum-arc device including: a consumable cathode including a first material having a defined active surface, a refractory anode including a second material, an inter-electrode volume, bounded partially by at least a portion of an inner wall of the cathode and by at least a portion of an inner wall of the anode, wherein at least a portion of the inner walls form a first chamber surrounding the inter-electrode volume, the chamber having at least one opening fluidly communicating between the inter-electrode volume and an a volume outside the chamber; a vacuum chamber, disposed around and communicating with the first chamber; an evacuation mechanism for evacuating the vacuum chamber; wherein the cathode is adapted, and the cathode and the anode are disposed, such that upon evacuating the vacuum chamber using the evacuation mechanism, ignition of an arc discharge between the cathode and the anode, and activation of a high-current power supply, a portion of the first material is liberated from the cathode, transported through the inter-electrode volume, and discharged from the first chamber through the opening, wherein: a total opening area of the at least one opening, Aopenings, is defined by a sum of a minimum cross-sectional area for each the opening, the cross-sectional area being normal to a path of the opening between the inter-electrode volume and the volume outside the chamber; a surface area of the anode, Aanode, is defined by a geometrical surface area of the portion of the anode that bounds the inter-electrode volume; and wherein a ratio of the surface area of the anode to the total opening area, A | 09-16-2010 |
| 20100216723 | NEUROPROTECTION USING NAP-LIKE AND SAL-LIKE PEPTIDE MIMETICS - This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease. | 08-26-2010 |
| 20100215239 | METHOD AND SYSTEM FOR CHARACTERIZING CORTICAL STRUCTURES - A method of identifying brain structures is disclosed. The method comprises imaging the cortex of the brain via inversion recovery magnetic resonance imaging, such that at least two areas are zeroed in terms of their longitudinal relaxation times, and associating the two areas with different brain structures, thereby identifying brain structures. | 08-26-2010 |
| 20100204469 | CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF - Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity. | 08-12-2010 |
| 20100203609 | PHOTOCATALYTIC HYDROGEN PRODUCTION AND POLYPEPTIDES CAPABLE OF SAME - An isolated polypeptide comprising a hydrogen generating enzyme attached to a heterologous ferredoxin is disclosed, as well as polynucleotides encoding same, nucleic acid constructs capable of expressing same and cells expressing same. A method for generating hydrogen using the isolated polypeptide is also disclosed. | 08-12-2010 |
| 20100203158 | ANTISEPTIC COMPOSITIONS AND USES THEREOF - Antiseptic compositions and kits containing a source of silver ions and menthol, which act in synergy such that a concentration of silver ions in the composition is substantially reduced, are disclosed. Further disclosed are uses of the antiseptic compositions as disinfectants and in the treatment of wounds. | 08-12-2010 |
| 20100194142 | METHODS AND APPARATUS FOR REDUCTION OF AERODYNAMIC DRAG - A method of reducing aerodynamic drag on a moving blunt-edged body, the method comprising actively generating a flow of air at a blunt edge of a body and using the generated flow of air to control an external flow of air moving relative to an edge of a moving blunt-body. | 08-05-2010 |
| 20100192043 | INTERRUPTION CRITERIA FOR BLOCK DECODING - While decoding a representation, imported from a channel, of a codeword that encodes K information bits as N>K codeword bits, by updating estimates of the codeword bits in a plurality of iterations, the iterations are interrupted upon satisfaction of an interruption criterion that is either an order-dependent interruption criterion or an interruption criterion that includes an estimate of mutual information of the codeword and a vector that is used in the decoding iterations. Either the iterations are terminated or the iterations are resumed after one or more elements of one or more vectors used in the iterations is/are modified. | 07-29-2010 |
| 20100192042 | READING A FLASH MEMORY BY CONSTRAINED DECODING - To read memory cells that have been programmed to store an ECC codeword, with each cell storing a respective plurality of bits of the codeword, a respective value of an operational parameter such as a threshold voltage of each cell is measured. Each bit is assigned a respective metric, such as a LLR estimate of the bit, based at least in part on the respective value of the operational parameter of the bit's cell. The metrics are decoded with reference both to the ECC and to mutual constraints of the metrics within each cell that are independent of the ECC. | 07-29-2010 |
| 20100190185 | NOVEL NON-INVASIVE MARKER FOR LIVER FUNCTION AND DISEASE - A monoclonal antibody or fragment thereof, capable of specifically binding to at least one epitope of sH2a and/or being elicited by at least one epitope, and assays, kits, and methods of use thereof diagnosing liver disease or condition, detecting liver function and assessing the efficacy of therapy to a liver disease. | 07-29-2010 |
| 20100189781 | ALKOXYALKYL S-PRENYLTHIOSALICYLATES FOR TREATMENT OF CANCER - Disclosed are alkoxyalkyl S-prenylthiosalicylates and pharmaceutical compositions containing the same and a pharmaceutically acceptable carrier. Methods for treating a human afflicted with cancer, including solid tumors, or a hematological malignancy by administering to the human in need thereof an effective amount of an alkoxyalkyl S-prenylthiosalicylate are also disclosed. | 07-29-2010 |
| 20100169737 | METHOD AND DEVICE FOR MULTI PHASE ERROR-CORRECTION - Data bits to be encoded are split into a plurality of subgroups. Each subgroup is encoded separately to generate a corresponding codeword. Selected subsets are removed from the corresponding codewords, leaving behind shortened codewords, and are many-to-one transformed to condensed bits. The final codeword is a combination of the shortened codewords and the condensed bits. A representation of the final codeword is decoded by being partitioned to a selected subset and a plurality of remaining subsets. Each remaining subset is decoded separately. If one of the decodings fails, the remaining subset whose decoding failed is decoded at least in part according to the selected subset. If the encoding and decoding are systematic then the selected subsets are of parity bits. | 07-01-2010 |
| 20100156679 | LINEARIZED OPTICAL DIGITAL-TO-ANALOG MODULATOR - A modulator device for converting digital data into modulation of an optical signal includes an electronic input for receiving an input data word of N bits and an electrically controllable modulator for modulating the intensity of an optical signal, the modulator including M actuating electrodes where M≧N. An electrode actuating device, most preferably a digital-to-digital converter, operates actuating electrodes so that at least one electrode is actuated as a function of values of more than one bit of the input data word. According to an alternative, or supplementary, aspect of the invention, the set of electrodes includes at least one electrode having an effective area which is not interrelated to others of the set by factors of two. In one preferred implementation, a Mach-Zehnder modulator also provides phase modulation to give QAM functionality. Another implementation employs a semiconductor laser. | 06-24-2010 |
| 20100144873 | TREATMENT OF MYOCARDITIS USING FTS - Disclosed are methods of treating myocarditis by—administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof. | 06-10-2010 |
| 20100137296 | N-PHENYL ANTHRANILIC ACID DERIVATIVES AND USES THEREOF - Compounds that can be used as openers or blockers of voltage-dependent potassium channels, and which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing or enhancing cortical and/or peripheral neuron activity, compositions containing same and methods utilizing same are disclosed. Also disclosed are modulators of voltage-dependent potassium channels, which exhibit blocking of a TRPV1 channel, and hence are useful in the treatment of TRPV1-related conditions. | 06-03-2010 |
| 20100136605 | SYSTEM FOR AND METHOD OF POSITIONING CELLS AND DETERMINING CELLULAR ACTIVITY THEREOF - A device for positioning at least one cell in at least one addressable position, the device comprising a substrate formed with at least one addressable pore and at least one channel embedded in the substrate and being in fluid communication with the at least one pore. The at least one pore and the at least one channel are designed and constructed such that an under-pressure formed in the at least one channel results in vacuum adherence of the at least one cell onto the at least one pore, such that a single cell is vacuum adhered onto a single pore. In one embodiment, the substrate is a non-conductive substrate and is further formed with one or more electrode structures, where each of the electrode structures is positioned in one of the pores. In an additional embodiment the device is designed locatable onto an organ, such as a brain. | 06-03-2010 |
| 20100136138 | TREATMENT OF LUNG CANCER - Disclosed are methods of treating lung cancer by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with a chemotherapeutic agent. Chemotherapeutic agents, and combinations thereof, for use with FTS, its analogs, or its salts are also disclosed. | 06-03-2010 |
| 20100133107 | METHOD FOR ELECTROCHEMICAL DEPOSITION OF MONOLAYERS ON METALLIC SURFACES AND OBJECTS COATED WITH AN ORGANIC MONOLAYER - The present invention generally provides methods for the electrodeposition of organic monolayers onto the surfaces of a great variety of objects. | 06-03-2010 |
| 20100130549 | PSYCHOTROPIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE - The present invention provides a method for treating or preventing a disease or disorder treatable by the inhibition of serotonin reuptake in a patient, and/or norepinephrine reuptake and/or dopamine reuptake in a patient, the method comprising administering to the patient a neurotransmitter reuptake inhibiting-effective amount of at least one compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogean halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR | 05-27-2010 |
| 20100120755 | Conjugated psychotropic drugs and uses thereof - Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity. | 05-13-2010 |
| 20100103953 | METHOD, APPARATUS AND COMPUTER-READABLE CODE FOR DATA COMPRESSION OF NETWORK PACKETS - Methods, apparatus and computer readable code for compression, encoding and decoding of units of data such as packets are disclosed. In some embodiments, methods, apparatus and computer readable code for transmitting and/or receiving the data packets (for example, transmitting from a sending location to a receiving location where packets are received) are provided. For at least some packets, a dictionary is determined from a respective group of packets, including a first set of historical packets and excluding a second set of historical packet. Each target packet is encoded and/or compressed and/or decoded using the respective dictionary. Optionally, the respective group of packet includes the actual target packet to be encoded and/or compressed and/or decoded. In some embodiments, respective group of packets from which the dictionary is determined includes packets that have not been acknowledged from the receiving location at the time of encoding, though embodiments where packets have been acknowledged are also disclosed. | 04-29-2010 |
| 20100093704 | NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY - The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders. | 04-15-2010 |
| 20100093600 | REGULATION OF NEUROTRANSMITTERS SEQUESTRATION AND RELEASE THROUGH MANIPULATION OF THE VESICULAR FUNCTIONS - A method of selecting an agent comprising a neuroprotecting activity is disclosed. The method comprises:
| 04-15-2010 |
| 20100087384 | JASMONATE BASED ASSAYS FOR IDENTIFYING COMPOUNDS THAT SELECTIVELY INHIBIT MITOCHONDRIAL BOUND HEXOKINASES - The present invention provides compositions comprising compounds that selectively bind to hexokinases thereby promoting dissociation of these enzymes from mitochondria, and methods of use of such compounds and compositions to induce cell death in diseases and disorders characterized by the high levels of mitochondrial bound hexokinase. The present invention further discloses methods and assays for detecting and identifying molecules having these activities. | 04-08-2010 |
| 20100082885 | METHOD AND SYSTEM FOR ADAPTIVE CODING IN FLASH MEMORIES - Bits are stored by attempting to set parameter value(s) of (a) cell(s) to represent some of the bits. In accordance with the attempt, an adaptive mapping of the bits to value ranges is provided and the value(s) is/are adjusted accordingly as needed. Or, to store (a) bit(s) in (a) cell(s), a default mapping of the bit(s) to a predetermined set of value ranges is provided and an attempt is made to set the cell value(s) accordingly. If, for one of the cells, the attempt sets the value such that the desired range is inaccessible, an adaptive mapping is provided such that the desired range is accessible. Or, to store (a) bit(s) in (a) cell(s), several mappings of the bit(s) to a predetermined set of ranges is provided. Responsive to an attempt to set the cell value(s) according to one of the mappings, the mapping to actually use is selected. | 04-01-2010 |
| 20100081933 | TREATING WEAKENED VESSEL WALL SUCH AS VULNERABLE PLAQUE OR ANEURYSMS - Described is a method of stabilizing blood vessel wall abnormality. The method includes ultrasonically heating at least a portion of the blood vessel wall having the abnormality; monitoring a parameter related to a property of at least a portion of the heated portion of the blood vessel wall; and stopping the heating when the monitored parameter changes by a predetermined factor or after the monitored parameter changes in a slow enough rate. The slow enough rate may be, for instance, a predetermined fraction of a maximal rate change observed during heating. | 04-01-2010 |
| 20100070692 | MULTI-BIT-PER-CELL FLASH MEMORY DEVICE WITH NON-BIJECTIVE MAPPING - To store a plurality of input bits, the bits are mapped to a corresponding programmed state of one or more memory cells and the cell(s) is/are programmed to that corresponding programmed state. The mapping may be many-to-one or may be an “into” generalized Gray mapping. The cell(s) is/are read to provide a read state value that is transformed into a plurality of output bits, for example by maximum likelihood decoding or by mapping the read state value into a plurality of soft bits and then decoding the soft bits. | 03-18-2010 |
| 20100063034 | Conjugated psychotropic drugs and uses thereof - Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity. | 03-11-2010 |
| 20100062143 | METHOD AND DEVICE FOR RADIOTHERAPY - A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor. | 03-11-2010 |
| 20100056591 | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators - Compounds, compositions and methods are provided which are useful in the treatment of conditions such as central or peripheral nervous system disorders through the modulation of potassium ion flux through voltage-dependent potassium channels and/or depressing cortical and/or peripheral neuron activity are disclosed. Novel derivatives of N-phenylanthranilic acid are also disclosed. | 03-04-2010 |
| 20100041166 | Method and system for detecting a target within a polupation of molecules | 02-18-2010 |
| 20100041069 | METHODS FOR DIAGNOSING AND MONITORING LIVER DISEASES - A method of diagnosing a liver disorder in a subject is disclosed. The method comprises determining a level of sH2A and at least one additional liver marker in a sample of the subject wherein a change beyond a predetermined threshold in both the sH2A and the at least one additional marker with respect to a sample from a healthy individual is indicative of the liver disorder. Kits for diagnosing a liver disorder are also disclosed. | 02-18-2010 |
| 20100027118 | Method and device for modification of surface properties of materials - A method and device are presented for modifying parameters of a solid material. This is implemented by applying radiation, such as photon flux and/or charged particle beam and/or heat, to at least a region of the material, and controlling at least one parameter of the applied radiation, thereby modifying a wettability property of the material within the irradiated region(s) thereof in a reversible manner. | 02-04-2010 |
| 20100021434 | Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases - Isolated human cells and populations thereof are provided comprising at least one oligodendrocyte phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an oligodendrocyte phenotype. Methods of generating and using same are also provided. | 01-28-2010 |
| 20100015042 | Combine radiation therapy and chemotherapy for treating cancer - A method of treating a tumor of a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of alpha particles and a chemotherapeutic agent, wherein the alpha particles are administered by positioning a non-stable alpha-emitting radionuclide in proximity to and/or within the tumor, so as to administer a dose of alpha particles into the tumor, wherein the method does not comprise administration of an inhibitor of DNA repair, thereby treating the tumor of the subject. | 01-21-2010 |
| 20100006958 | Tilting Actuator with Close-Gap Electrodes - An electromechanical tilting device including a first and a second electrode structures, shaped, positioned and oriented to define at least partially interdigitated electrodes, and a suspension defining a tilt-containing motion path for the second structure with respect to the first structure. The motion path is selected to cause changes in overlapping regions and overlapping regions' gaps of the interdigitated electrodes. The device is configured such that an increase in one or more voltage bias applied to interdigitated driving electrodes makes a decrease in a total area of overlapping regions of the driving electrodes electrically energetically favorable. | 01-14-2010 |
| 20100005370 | PROBABILISTIC ERROR CORRECTION IN MULTI-BIT-PER-CELL FLASH MEMORY - Data that are stored in cells of a multi-bit-per cell memory, according to a systematic or non-systematic ECC, are read and corrected (systematic ECC) or recovered (non-systematic ECC) in accordance with estimated probabilities that one or more of the read bits are erroneous. In one method of the present invention, the estimates are a priori. In another method of the present invention, the estimates are based only on aspects of the read bits that include significances or bit pages of the read bits. In a third method of the present invention, the estimates are based only on values of the read bits. Not all the estimates are equal. | 01-07-2010 |
| 20100005367 | PROBABILISTIC ERROR CORRECTION IN MULTI-BIT-PER-CELL FLASH MEMORY - Data that are stored in cells of a multi-bit-per cell memory, according to a systematic or non-systematic ECC, are read and corrected (systematic ECC) or recovered (non-systematic ECC) in accordance with estimated probabilities that one or more of the read bits are erroneous. In one method of the present invention, the estimates are a priori. In another method of the present invention, the estimates are based only on aspects of the read bits that include significances or bit pages of the read bits. In a third method of the present invention, the estimates are based only on values of the read bits. Not all the estimates are equal. | 01-07-2010 |
| 20090327841 | PROBABILISTIC ERROR CORRECTION IN MULTI-BIT-PER-CELL FLASH MEMORY - Data that are stored in cells of a multi-bit-per cell memory, according to a systematic or non-systematic ECC, are read and corrected (systematic ECC) or recovered (non-systematic ECC) in accordance with estimated probabilities that one or more of the read bits are erroneous. In one method of the present invention, the estimates are a priori. In another method of the present invention, the estimates are based only on aspects of the read bits that include significances or bit pages of the read bits. In a third method of the present invention, the estimates are based only on values of the read bits. Not all the estimates are equal. | 12-31-2009 |
| 20090324554 | METHOD FOR INHIBITING OR TREATING A DISEASE ASSOCIATED WITH INTRACELLULAR FORMATION OF PROTEIN FIBRILLAR OR AGGREGATES - A therapeutic agent which carries a peptide sequence containing a mammalian cell adhesion sequence can be used to inhibit or treat diseases associated with intracellular formation of protein fibrillar inclusions or aggregates, to inhibit the intracellular formation of protein fibrillar inclusions or aggregates, and to disaggregate pre-formed intracellular protein fibrillar inclusions or aggregates. Filamentous bacteriophage which displays a non-filamentous bacteriophage RGD cell adhesion sequence on its surface, but not an antibody or non-filamentous bacteriophage antigen other than said RGD cell adhesion sequence, is a preferred embodiment of such a therapeutic agent. | 12-31-2009 |
| 20090319868 | READING A FLASH MEMORY BY JOINT DECODING AND CELL VOLTAGE DISTRIBUTION TRACKING - To read a plurality of memory cells, each cell is assigned to a respective cell population. A respective value of an operational parameter of each cell is measured. Each cell is assigned an a-priori metric based at least in part on one or more CVD parameter values of the cell's population. The a-priori metrics are decoded. Based at least in part on the resulting a-posteriori metrics, the CVD parameter values are corrected, without repeating the measurements of the cell operational parameter values. The operational parameter values are indicative of bit patterns stored in the cells, and the correction of the CVD parameter values is constrained by requiring the bit patterns collectively to be a valid codeword. | 12-24-2009 |
| 20090319861 | USING DAMPING FACTORS TO OVERCOME LDPC TRAPPING SETS - To decode a representation, imported from a channel, of a codeword that encodes K information bits as N>K codeword bits, estimates of the codeword bits are updated by exchanging messages between N bit nodes and N−K check nodes of a graph in a plurality of iterations. In each of one or more of the iterations, some or all values associated with the bit nodes, and/or some or all values associated with check nodes, and/or some or all messages are modified in a manner that depends explicitly on the ordinality of the iteration and is independent of any other iteration. Alternatively, the modifications are according to respective locally heteromorphic rules. | 12-24-2009 |
| 20090319860 | OVERCOMING LDPC TRAPPING SETS BY DECODER RESET - To decode, in a plurality of iterations, a representation, imported from a channel, of a codeword that encodes K information bits as N>K codeword bits, estimates of the codeword bits are updated by exchanging messages between N bit nodes and N−K check nodes of a graph. If the decoding has failed to converge according to a predetermined failure criterion and if the codeword bit estimates satisfy a criterion symptomatic of the graph including a trapping set, at least a portion of the messages are reset before continuing the iterations. Alternatively, if the decoding fails to converge according to a predetermined failure criterion, at least a portion of the messages that are sent from the bit nodes are truncated before continuing the iterations. | 12-24-2009 |
| 20090319858 | REDUCED COMPLEXITY LDPC DECODER - To decode a manifestation of a codeword in which K information bits are encoded as N>K codeword bits, messages are exchanged between N bit nodes and N−K check nodes. During computation, messages are expressed with a full message length greater than two bits. In each iteration, representations of at least some of the exchanged messages are stored. For at least one node, if representations of messages sent from that node are stored, then the representation of one or more of the messages is stored using at least two bits but using fewer bits than the full message length, and the representation of one other message is stored with full message length. Preferably, the messages that are stored using fewer bits than the full message length are messages sent from check nodes. | 12-24-2009 |
| 20090311413 | METHOD AND DEVICE FOR RADIOTHERAPY - A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor. | 12-17-2009 |
| 20090311173 | METHOD AND DEVICE FOR RADIOTHERAPY - A radiotherapy method, comprising positioning a predetermined amount of a radionuclide selected from the group consisting of Radium-223, Radium-224, Radon-219 and Radon-220, in proximity to and/or within a tumor of a subject, for a predetermined time period. The predetermined amount and the predetermined time period are selected sufficient for the radionuclide to administering a predetermined therapeutic dose of decay chain nuclei and alpha particles into the tumor. | 12-17-2009 |
| 20090304726 | VIRAL DISPLAY VEHICLES FOR TREATING MULTIPLE SCLEROSIS - Provided are viral display vehicles which display multiple sclerosis associated antigens on the surface thereof for induction of immune tolerance to autoantigens such as MOG. Also provided are methods and pharmaceutical compositions for treating multiple sclerosis using the viral display vehicles of the present invention. | 12-10-2009 |
| 20090304584 | CONJUGATES COMPRISING A GABA- OR GLYCINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF AND THEIR USE IN TREATING CNS DISORDERS - Conjugates of a gamma-aminobutyric acid (GABA) compound or a glycine compound and an analgesic drug are disclosed. Further disclosed are pharmaceutical compositions containing these conjugates and uses thereof in the treatment of CNS-associated diseases or disorders, optionally in combination with a psychotropic drug. | 12-10-2009 |
| 20090298843 | TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH FTS AND A BCR-ABL TYROSINE KINASE INHIBITOR - Disclosed are methods of treating a hematological malignancy by administering to a human in need thereof effective amounts of FTS (Farnesylthiosalicylic Acid), or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally in combination with a Bcr-Abl tyrosine kinase inhibitor. Also disclosed are pharmaceutical compositions comprising FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, a Bcr-Abl tyrosine kinase inhibitor, preferably Imatinib and a pharmaceutically acceptable carrier. | 12-03-2009 |
| 20090286870 | Cancer Treatment Using FTS and 2-Deoxyglucose - Methods of treating cancer by administering effective amounts of a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2-deoxyglucose (2DG) to a patient are disclosed. Pharmaceutical compositions useful in treating cancer containing a Ras antagonist comprising FTS, or analogs thereof, or a pharmaceutically acceptable salt, and 2DG are also disclosed. | 11-19-2009 |
| 20090280123 | Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same - An isolated polynucleotide comprising a nucleic acid sequence encoding a KIF18A polypeptide being expressed in mesenchymal stem cells is disclosed. Methods of detecting same are disclosed as well as methods of using same for modulating estrogen signaling in cells. | 11-12-2009 |
| 20090280114 | PREVENTION OF BRAIN INFLAMMATION AS A RESULT OF INDUCED AUTOIMMUNE RESPONSE - A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors of the patient are blocked, preferably by administration of an effective amount of IVIg, prior to the procedure of causing the antibodies to come into contact with the amyloid. | 11-12-2009 |
| 20090257987 | Method of generating dopamine-secreting cells - Methods of generating cells which secrete dopamine are disclosed. One method comprises incubating mesenchymal stem cells in a culture medium comprising brain derived neurotrophic factor (BDNF), wherein the culture medium comprises no more than 0.1 μM retinoic acid (RA). Another method comprises incubating mesenchymal stem cells in a culture medium comprising glial-derived neurotrophic factor GDNF, transforming growth factor β3 (TGFβ3) and retinoic acid (RA). Cells generated by the above-described methods are also disclosed as well as uses thereof. | 10-15-2009 |
| 20090242879 | Optoelectronic device and method of fabricating the same - A modified isolated polypeptide comprising an amino acid sequence encoding a photocatalytic unit of a photosynthetic organism being capable of covalent attachment to a solid surface and having a photocatalytic activity when attached thereto is disclosed. | 10-01-2009 |
| 20090236539 | Method for generating surface plasmon emission - A nanostructure is used to generate a highly localized nanoscale optical field. The field is excited using surface plasmon amplification by stimulated emission of radiation (SPASER). The SPASER radiation consists of surface plasmons that undergo stimulated emission, but in contrast to photons can be localized within a nanoscale region. A SPASER can incorporate an active medium formed by two-level emitters, excited by an energy source, such as an optical, electrical, or chemical energy source. The active medium may be quantum dots, which transfer excitation energy by radiationless transitions to a resonant nanosystem that can play the same role as a laser cavity in a conventional laser. The transitions are stimulated by the surface plasmons in the nanostructure, causing the buildup of a macroscopic number of surface plasmons in a single mode. | 09-24-2009 |
| 20090232740 | Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease - A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with said substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of said electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy. | 09-17-2009 |
| 20090222949 | Constructs and Methods for Generating Plants Exhibiting Altered Plasmodesmatal Conductance - A plant cell including a heterologous polynucleotide sequence capable of directing overexpression of a reversibly glycosylated polypeptide or a functional portion thereof is provided. | 09-03-2009 |
| 20090220483 | Stable Enzymatic Preparations and Methods of Use Thereof - The present invention relates to stable concentrated enzymatic compositions suitable for storage under ambient conditions, while maintaining their intended enzymatic activity. The invention further relate to kits comprising concentrated enzymatic compositions, methods for preparing debriding solutions from said concentrated enzymatic compositions and methods of using the diluted debriding solutions. | 09-03-2009 |
| 20090220184 | Electro-Optical Modulator Structure - The present invention discloses an ultra-compact optical modulator comprising at least one resonator on a semiconductor chip. The EO modulator modulates incoming light having a certain wavelength range and comprises a waveguide layer accommodating at least one resonator having a periodic complex refraction index distribution structure defining a periodic defect band-edge and a cladding layer; and at least one electrode; the waveguide layer, the cladding layer and the electrode forming a capacitor structure; such that when an external voltage is applied to the capacitor structure the free carrier concentration in the waveguide layer is controlled, enabling a modulation of the resonator's refractive index; wherein the periodic defect band-edge is selected to be within the wavelength range, enabling a slow-light propagation of the incoming light within the waveguide layer. | 09-03-2009 |
| 20090217131 | PROBABILISTIC ERROR CORRECTION IN MULTI-BIT-PER-CELL FLASH MEMORY - Data that are stored in cells of a multi-bit-per cell memory, according to a systematic or non-systematic ECC, are read and corrected (systematic ECC) or recovered (non-systematic ECC) in accordance with estimated probabilities that one or more of the read bits are erroneous. In one method of the present invention, the estimates are a priori. In another method of the present invention, the estimates are based only on aspects of the read bits that include significances or bit pages of the read bits. In a third method of the present invention, the estimates are based only on values of the read bits. Not all the estimates are equal. | 08-27-2009 |
| 20090217124 | METHOD AND DEVICE FOR MULTI PHASE ERROR-CORRECTION - Data bits to be encoded are split into a plurality of subgroups. Each subgroup is encoded separately to generate a corresponding codeword. Selected subsets are removed from the corresponding codewords, leaving behind shortened codewords, and are many-to-one transformed to condensed bits. The final codeword is a combination of the shortened codewords and the condensed bits. A representation of the final codeword is decoded by being partitioned to a selected subset and a plurality of remaining subsets. Each remaining subset is decoded separately. A subset whose decoding is terminated is decoded again, at least in part according to the selected subset. If the encoding and decoding are systematic then the selected subsets are of parity bits. | 08-27-2009 |
| 20090203615 | USE OF ACTIVITY DEPENDENT NEUROTROPHIC FACTOR FOR ENHANCING LEARNING AND MEMORY: PRE-AND POST-NATAL ADMINISTRATION - The present invention provides methods for improving performance (e.g., learning and/or memory) using ADNF polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject. | 08-13-2009 |
| 20090186027 | SINGLE CHAIN ANTIBODIES AGAINST BETA-AMYLOID PEPTIDE - Anti-AβP scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Abp 1-40 and disaggregate Abp 1-40 fibrils generated in vitro. The anti-Aβp scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-ABP scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease. | 07-23-2009 |
| 20090183049 | PROBABILISTIC ERROR CORRECTION IN MULTI-BIT-PER-CELL FLASH MEMORY - Data that are stored in cells of a multi-bit-per cell memory, according to a systematic or non-systematic ECC, are read and corrected (systematic ECC) or recovered (non-systematic ECC) in accordance with estimated probabilities that one or more of the read bits are erroneous. In one method of the present invention, the estimates are a priori. In another method of the present invention, the estimates are based only on aspects of the read bits that include significances or bit pages of the read bits. In a third method of the present invention, the estimates are based only on values of the read bits. Not all the estimates are equal. | 07-16-2009 |
| 20090180991 | METHOD FOR TREATING INFLAMMATION ASSOCIATED WITH AMYLOID DEPOSITS AND BRAIN INFLAMMATION INVOLVING ACTIVATED MICROGLIA - Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits. | 07-16-2009 |
| 20090176303 | Method and apparatus for propagating benthic marine invertebrates - An apparatus for propagating benthic marine invertebrates in water. The apparatus comprises (a) a culture cell, (b) a sedimentation chamber in fluid connection with the culture cell, and (c) a pump in fluid connection with the culture cell and with the sedimentation chamber capable of pumping water from the sedimentation chamber to the culture cell. Also disclosed is a method for propagating benthic marine invertebrates comprising culturing the invertebrates in a water environment in the apparatus. | 07-09-2009 |
| 20090170780 | PROTECTION OF THE RETINA AGAINST LASER INJURY BY NAP AND RELATED PEPTIDES - This invention relates to the use of ADNF polypeptides in the treatment of laser-induced retinal damage and related conditions. | 07-02-2009 |
| 20090168151 | APPARATUS AND METHODS FOR OPTICAL AMPLIFICATION IN SEMICONDUCTORS - Methods and corresponding apparatus for optical amplification in semiconductors, particularly indirect band-gap semiconductors, and most particularly in silicon. A first aspect of the invention employs certain doping elements to provide inter-band-gap energy levels in combination with optical or current-injection pumping. The doping element, preferably a noble metal and most preferably Gold, is chosen to provide an energy level which enables an energy transition corresponding to a photon of wavelength equal to the signal wavelength to be amplified. The energy transition may be finely “adjusted” by use of standard doping techniques (such as n-type or p-type doping) to alter the conduction and valence band energy levels and thereby also the magnitude of the energy transition. A second aspect of the invention relates to the use of a non-homogeneous heat distribution which has been found to lead to optical amplification effects. | 07-02-2009 |
| 20090163405 | Angiogenic peptides and uses thereof - A peptide comprising an amino acid sequence as set forth in SEQ ID NO: 2, 4, 6, 8, 10 or 12 is provided. The peptide being at least 6 and no more than 50 amino acid residues in length. Also provided are therapeutic applications using such peptides. | 06-25-2009 |
| 20090156471 | Use of anti-amyloid agents for treating and typing pathogen infections - A method of preventing or treating a pathogen infection in a subject is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an anti amyloid agent, thereby treating or preventing the pathogen infection in the subject. | 06-18-2009 |
| 20090155178 | LIPIDATED GLYCOSAMINOGLYCAN PARTICLES AND THEIR USE IN DRUG AND GENE DELIVERY FOR DIAGNOSIS AND THERAPY - Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal. | 06-18-2009 |
| 20090127112 | Biologically active metal-coated proteins - Metal-coated proteins, being dissolvable or suspendable in aqueous media and/or retaining a biological activity of the protein, a process and intermediates for preparing same are disclosed. Further disclosed are a pharmaceutical composition containing and a method of treating bacterial and fungal infections utilizing biologically active metal-coated proteins. Conductive elements, electronic circuits containing same, electrodes and biosensor systems utilizing same, and imaging probes, all containing the metal-coated proteins, are also disclosed. | 05-21-2009 |
| 20090124543 | ACTIVITY DEPENDENT NEUROTROPHIC FACTOR III (ADNF III) - The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) β-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease. | 05-14-2009 |
| 20090123553 | Peptide nanostructures and methods of generating and using the same - A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid. | 05-14-2009 |
| 20090121709 | Peptide nanostructures encapsulating A foreign material and method of manufacturing same - A composition comprising a material at least partially enclosed by a tubular, spherical or planar nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid. | 05-14-2009 |
| 20090095412 | Nanotube network and method of fabricating the same - A stamping device for stamping a nanotube network onto a target substrate is disclosed. The device comprises a template structure having a support structure formed on or attached to a substrate, and a plurality of nanotubes being supported by the support structure and engaging a plane which is spatially separated from the substrate. | 04-16-2009 |
| 20090070657 | METHOD OF ERROR CORRECTION IN MBC FLASH MEMORY - A plurality of logical pages is stored in a MBC flash memory along with corresponding ECC bits, with at least one of the MBC cells storing bits from more than one logical page, and with at least one of the ECC bits applying to two or more of the logical pages. When the pages are read from the memory, the data bits as read are corrected using the ECC bits as read. Alternatively, a joint, systematic or non-systematic ECC codeword is computed for two or more of the logical pages and is stored instead of those logical pages. When the joint codeword is read, the logical bits are recovered from the codeword as read. The scope of the invention also includes corresponding memory devices, the controllers of such memory devices, and also computer-readable storage media bearing computer-readable code for implementing the methods. | 03-12-2009 |
| 20090066964 | DISPLACEMENT SENSOR BASED ON PHOTONIC CRYSTAL WAVEGUIDES - A displacement sensor comprising at least one pair of co-planar photonic crystal waveguide (PCWG) sections aligned along or parallel to a common axis and separated by a gap, one PCWG section of a pair operative to perform a displacement relative to the other section of the pair. In some embodiments, the sensor is linear, comprising two PCWG sections separated by a gap that forms a cross PCWG, the displacement sensing performed preferrably differentially between two edges of the cross PCWG. In other embodiments, the sensor includes Mach Zehnder Interferometer (MZI) configurations with gaps between fixed and moving PCWG sections. Displacement induced changes in the gap widths are reflected in changes in an output parameter of the MZI. | 03-12-2009 |
| 20090061190 | ARTICLES OF PEPTIDE NANOSTRUCTURES AND METHOD OF FORMING THE SAME - A method of forming a fiber made of peptide nanostructures is disclosed. The method comprises: providing peptide nanostructures in solution, and fiberizing the solution thereby forming at least one fiber of the peptide nanostructures. Also disclosed are methods of forming films and other articles using the peptide nanostructures. | 03-05-2009 |
| 20090034649 | Constructive method of peak power reduction in multicarrier transmission - A plurality of bits is transmitted by partitioning the bits among n subsets; encoding each subset as a respective symbol; selecting a balancing vector, in accordance with the symbols, from a set of size 2 | 02-05-2009 |
| 20090027754 | PHOTONIC CRYSTAL RESONATOR, A COUPLED CAVITY WAVEGUIDE, AND A GYROSCOPE - A rotating optical resonator, a waveguide and a method of use of waveguide are disclosed. The rotating optical resonator may include at least two modes of different resonant frequencies shiftable towards each other by reducing a magnitude of rotation rate, said modes being joinable into a substantially degenerate mode by setting substantially zero rotation rate, said resonator being of an optical size smaller than five wavelengths of the substantially degenerate mode. The waveguide may include a plurality of coupled evenly degenerate split mode resonators, the split of the modes forming a stop band in a resonant band of the waveguide, the stop band of the waveguide thereby being changeable by changing an angular velocity of the waveguide while the vector of the angular velocity is non-parallel with respect to the waveguide. | 01-29-2009 |
| 20090010895 | Isolated cells and populations comprising same for the treatment of CNS diseases - An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype. | 01-08-2009 |
| 20080319066 | Jasmonate Derivative Compounds, Pharmaceuticals Compounds and Methods of Use Thereof - The present invention provides novel jasmonate derivative compounds, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for treatment of cancers, especially mammalian cancers. | 12-25-2008 |
| 20080317423 | Embedded Channels, Embedded Waveguide And Methods Of Manufacturing And Using The Same - Waveguide(s) ( | 12-25-2008 |
| 20080314272 | Printing method and apparatus - Disclosed are a printing method and apparatus which utilizes surface modification of a substrate on which an indicia pattern is to be created. | 12-25-2008 |
| 20080294960 | MEMORY-EFFICIENT LDPC DECODING - To decode a representation of a codeword that encodes K information bits as N>K codeword bits, messages are exchanged between N bit nodes and N−K check nodes of a graph in which E edges connect the bit nodes and the check nodes. While messages are exchanged, fewer than E of the messages are stored, and/or fewer than N soft estimates of the codeword bits are stored. In some embodiments, the messages are exchanged only within sub-graphs and between the sub-graphs and one or more external check nodes. While messages are exchanged, the largest number of stored messages is the number of edges in the sub-graph with the most edges plus the number of edges that connect the sub-graphs to the external check node(s), and/or the largest number of stored soft estimates is the number of bit nodes in the sub-graph with the most bit nodes. | 11-27-2008 |
| 20080291724 | MULTI-BIT-PER-CELL FLASH MEMORY DEVICE WITH NON-BIJECTIVE MAPPING - To store a plurality of input bits, the bits are mapped to a corresponding programmed state of one or more memory cells and the cell(s) is/are programmed to that corresponding programmed state. The mapping may be many-to-one or may be an “into” generalized Gray mapping. The cell(s) is/are read to provide a read state value that is transformed into a plurality of output bits, for example by maximum likelihood decoding or by mapping the read state value into a plurality of soft bits and then decoding the soft bits. | 11-27-2008 |
| 20080266626 | All-Optical Devices and Methods for Data Processing - An all-optical device for data processing is presented. The device comprises at least one optical waveguide unit ( | 10-30-2008 |
| 20080263265 | ADAPTIVE DYNAMIC READING OF FLASH MEMORIES - Each of a plurality of flash memory cells is programmed to a respective one of L≧2 threshold voltage states within a threshold voltage window. Values of parameters of threshold voltage functions are adjusted in accordance with comparisons of the threshold voltages of some or all of the cells to two or more of m≧2 threshold voltage intervals within the threshold voltage window. Reference voltages for reading the cells are selected based on the values. Alternatively, the m threshold voltage intervals span the threshold voltage window, and respective threshold voltage states are assigned to the cells based on numbers of cells whose threshold voltages are in the intervals, without re-reading the cells. | 10-23-2008 |
| 20080241169 | IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY - A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization. | 10-02-2008 |
| 20080226619 | Anti-Muc1 Alpha/Beta Antibodies - The present invention provides antibodies that simultaneously bind the α- and β-subunits of an intact MUC1 protein, and methods for making and using such antibodies. | 09-18-2008 |
| 20080222066 | CALIBRATION AND PROFILE BASED SYNOPSES ERROR ESTIMIATION AND SYNOPSES RECONCILIATION - Apparatus, methods and computer code for estimating a synopsis error are disclosed herein. In some embodiments, one or more queries of a query workload are analyzed without running the analyzed queries. In some embodiments, the synopsis error is first estimated for a first memory allocation vector, and then, using intermediate or final results of the first estimated, estimated for a second memory allocation vector. In some embodiments, teachings related to estimating synopsis error are applied to the memory reconciliation problem. | 09-11-2008 |
| 20080210016 | Using Pulsed-Wave Ultrasonography For Determining an Aliasing-Free Radial Velocity Spectrum of Matter Moving in a Region - Using pulsed-wave (PW) ultrasonography for determining an aliasing-free radial velocity spectrum of matter moving in a region. Includes: transmitting into the region a plurality of pulse trains of sound waves at two or more different pulse repetition frequencies; spectrally analyzing each pulse train, for evaluating a Doppler frequency spectrum associated with each pulse train; combining frequency components of Doppler frequency spectrum of each pulse train, for obtaining aliasing-free instantaneous Doppler frequency spectrum for the region; using Doppler effect for translating aliasing-free frequency spectrum to aliasing-free radial velocity spectrum. Implementable using pulsed-wave Doppler (PWD), color flow Doppler (CFD), tissue Doppler imaging (TDI), or pulsed-wave (PW) ultrasonography. Applicable to liquid or/and solid forms of matter, moving in a two- or three-dimensional region. Matter is any substance or material, composed of organics or/and inorganics, which is part of a non-living object, or, part of a human or animal subject. | 09-04-2008 |
| 20080205791 | METHODS AND SYSTEMS FOR USE IN 3D VIDEO GENERATION, STORAGE AND COMPRESSION - A memory storage device readable by machine is presented, the device tangibly embodying a sequence of depth maps associated with a continuous scene sequence of digital 2D images of a predetermined resolution, the sequence of depth maps including at least one restricted redundancy depth map of a resolution lower than the predetermined resolution of the 2D images. The depth maps may be used for 3D (i.e. stereo) visualization. | 08-28-2008 |
| 20080200820 | System for determining endothelial dependent vasoactivity - A method of determining endothelial dependent vasoactivity of a subject, the method is effected by recording pressure-related signals of a plurality of locations adjacent to at least one blood vessel; extracting at least one parameter from the pressure-related signals; and using the at least one parameter to determine a change of at least one characteristic of the at least one blood vessel, the change being representative of endothelial functioning; thereby determining the endothelial dependent vasoactivity of the subject. | 08-21-2008 |
